Press release
PARP inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Download DelveInsight's comprehensive PARP inhibitor Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ PARP inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the PARP inhibitor Pipeline Report
* On 28 August 2025, AstraZeneca announced a study is a Phase I/IIa modular, open-label, multi-center study of AZD5335 administered either as monotherapy or in combination with other anti-cancer agents in participants with advanced solid malignancies.
* On 26 August 2025, Marc Dall'Era, MD conducted a phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
* On 26 August 2025, EMD Serono Research & Development Institute, Inc. announced a study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.
* DelveInsight's PARP inhibitor pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PARP inhibitor treatment.
* The leading PARP inhibitor Companies such as TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others
* Promising PARP inhibitor Therapies such as Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin and others.
Access DelveInsight's in-depth PARP inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ PARP inhibitor Clinical Trials and Studies [https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
PARP inhibitor Emerging Drugs Profile
* Pamiparib: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.
The PARP inhibitor Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of PARP inhibitor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PARP inhibitor Treatment.
* PARP inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* PARP inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PARP inhibitor market.
Get a detailed analysis of the latest innovations in the PARP inhibitor pipeline. Explore DelveInsight's expert-driven report today! @ PARP inhibitor Unmet Needs [https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
PARP inhibitor Companies
TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others.
PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
PARP inhibitor Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming PARP inhibitor Therapies and key Developments @ PARP inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the PARP inhibitor Pipeline Report
* Coverage- Global
* PARP inhibitor Companies- TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics and others
* PARP inhibitor Therapies- Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin and others.
* PARP inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* PARP inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive PARP inhibitor Pipeline Report-access it now! @ PARP inhibitor Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* PARP Inhibitors: Overview
* Structure
* Mechanism of Action
* Pipeline Therapeutics
* Comparative Analysis
* Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
* PARP Inhibitors - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* PARP Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends
* PARP Inhibitors Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
* Late Stage Products (Phase III)
* Comparative Analysis
* Pamiparib: BeiGene
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Comparative Analysis
* Drug Name: Company Name
* Product Description
* Research and Development
* Product Development Activities
* Drug profiles in the detailed report.....
* Inactive Products
* Comparative Analysis
* PARP Inhibitors Key Companies
* PARP Inhibitors Key Products
* PARP Inhibitors- Unmet Needs
* PARP Inhibitors- Market Drivers and Barriers
* PARP Inhibitors- Future Perspectives and Conclusion
* PARP Inhibitors Analyst Views
* PARP Inhibitors Key Companies
* 51. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parp-inhibitor-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PARP inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4165727 • Views: …
More Releases from ABNewswire
PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2025: Emerging Therap …
DelveInsight's "PD-1 and PD-L1 Inhibitors Competitive landscape 2025" report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving PD-1 and PD-L1 Inhibitors Pipeline and discover which companies are leading the innovation…
HER2-mutant NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA …
DelveInsight's "HER2-mutant NSCLC Pipeline Insights 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HER2-mutant NSCLC pipeline landscape. It covers the HER2-mutant NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive HER2-mutant NSCLC Pipeline…
Colorectal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA …
DelveInsight's, "Colorectal Cancer Pipeline Insight 2025" report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Colorectal…
Accounts Payable Services by IBN Technologies Gain Wider Adoption as Businesses …
Accounts payable services are becoming essential as businesses face rising demands for compliance, accuracy, and vendor coordination. Companies are turning to structured outsourced solutions to streamline invoice handling, reduce errors, and prepare for audits. The news highlights how organizations are gaining efficiency, better financial oversight, and stronger vendor relationships through enhanced accounts payable management.
Miami, Florida, 01 Sep 2025 Businesses worldwide are recognizing the growing importance of financial accountability as ecosystems…
More Releases for PARP
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
Parp Inhibitors Market Driven by Demand for Immersive Technologies Across Indust …
Global Parp Inhibitors Market Impact of AI and Automation
The PARP inhibitors market has seen remarkable growth in recent years, primarily driven by advances in cancer treatment and the increasing prevalence of cancer globally. These inhibitors, which block the enzyme poly (ADP-ribose) polymerase (PARP), are proving to be highly effective in targeting specific cancer cells, especially in cancers with DNA repair deficiencies like ovarian, breast, and prostate cancers. The approval of…
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
